Qiming Venture capital William: Entrepreneurial investors behind Tiger medicine

The venture industry is at a cyclical low level, when the weak cycle of health care is recognized. In August, Tiger Medicine was listed on the gem, the investor is Qiming Venture partner William, of course, he involves more than the project.　　His investment in the past few years also reflects the understanding of the Qiming team in this area.　　Miss William was whenever, born in October 1975. Graduated from Shanghai Medical University.　　Of course, 2000 Shanghai Medical University merged with Fudan, now Fudan University Medical School. After graduation into the pharmaceutical industry, sales, sales management.　　There seems to be nothing to do with the subsequent venture investment. The change took place in Shanghai Colorcon, William once served as product manager.　　Founded in 1961, the company is headquartered in Philadelphia, United States, is a global pharmaceutical accessories suppliers. This has the opportunity to comb the domestic pharmaceutical industry's large factories and research institutions. The company's database has thousands of customers, while the entire domestic pharmaceutical enterprises but six thousand or seven thousand.　　Working in Colorcon for two years, William said it was an important step in his understanding of the domestic pharmaceutical industry. After that, Citic future investment needs one, familiar with the domestic medical field of people, William joined in, as investment department manager.　　At that time the company is not big, two bosses, two investment managers, one to invest in it, one is he.　　CITIC Future investment in the work of more than a year, contact with the Shandong Green Leaf Pharmacy, as well as drug Wuxi.　　William recalls full of regrets, two companies are listed, but their investment has not been implemented, especially the drug Wuxi.　　Drug Wuxi involves a concept cro,contract research from, a contract study organization.　　New drug research and development can be divided into four stages: discovery and screening, preclinical research, clinical research, New drug reporting and follow-up work. In the 80 's, with the FDA's increasingly rigorous management of new drug research and development, research and development took longer and costs became unbearable. Therefore, the organization through the contract form for pharmaceutical enterprises in the research and development process to provide professional services.　　To pharmaceutical enterprises can improve the concentration of resources.　　CRO can reduce the management cost of pharmaceutical enterprises and improve the efficiency greatly. Cro is divided into preclinical CRO and clinical trial CRO: Preclinical CRO including compound research services, etc. The clinical trial CRO includes the phase I to IV clinical trial Technical Service, clinical trial data management, etc.　　In addition, also subdivided the new Drug application for approval and other business Cro. Li Ge, founder of Pharmaceutical Wuxi, graduated from the Department of Chemistry at Peking University in 1989 and received his Ph. D. In organic chemistry at Columbia University in 1993. When choosing the next stop, I was thinking about being a professor, and the tutor asked him if he would consider joining his own project set up the start-up company, the Inviter is the teacher, "is our own patented technology," so became one of the founders of Pharmacopoeia Company, 1995 year-end company on the Nasdaq listing.　　Later returned to business. At the end of 2002, William began to contact the drug Wuxi. William remembers that the company was also over 30 people. By the end of June 2, nearly unanimous, near the signing, "for our own reasons", the investment has not been implemented.　　This is the opportunity to pass by. The follow-up to this matter is August 9, 2007, the drug Wuxi parent company Wuxi PharmaTech (Cayman) Inc. landed on the New York Stock Exchange.　　According to 2006 earnings, Wuxi's clients included 9 of the world's top 10 Chinese pharmaceutical companies. After leaving Citic's future investment, William into IBM BCS, business consulting and system integration services, and later as a senior strategic consultant.　　After IBM's 3.5 billion dollar merger with PwC in 2002, two businesses were again integrated into BCS. Time flies, in a meeting, William met Shiping. Shiping offers the opportunity to invest in local decision-making institutions. Since then, William and Gary Rieschel and other major partners after the exchange of two-way choice, he joined the qiming.